Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 5;7(2):ofaa044.
doi: 10.1093/ofid/ofaa044. eCollection 2020 Feb.

Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017

Julia L Marcus  1   2 , Leo B Hurley  1 , Scott Chamberland  3 , Jamila H Champsi  4 , Daniel G Korn  5 , Jennifer B Lai  6 , Jennifer O Lam  1 , Charles P Quesenberry Jr  1 , Joanna Ready  7 , Varun Saxena  4 , Suk I Seo  8   9 , David J Witt  6 , Michael J Silverberg  1
Affiliations

Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017

Julia L Marcus et al. Open Forum Infect Dis. .

Abstract

Among 25 291 and 4 921 830 people with and without hepatitis C, life expectancy at age 20 increased 1.8 years and 0.3 years from the interferon to interferon-free era, respectively. Increases were highest for racial and/or ethnic minority groups with hepatitis C.

Keywords: direct-acting antiviral agents; hepatitis C virus (HCV); mortality; survival; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Life expectancy at age 20 for people with and without hepatitis C virus (HCV) by treatment era and for people with HCV by sex and race/ethnicity.
See this image and copyright information in PMC

References

    1. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis 2016; 62:1287–8. - PMC - PubMed
    1. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017; 9:CD012143. - PMC - PubMed
    1. Powderly WG, Naggie S, Kim AY, et al. IDSA/AASLD response to cochrane review on direct-acting antivirals for hepatitis C. Clin Infect Dis 2017; 65:1773–5. - PubMed
    1. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 68:827–38. - PubMed
    1. McGlynn EA, Adams JL, Kramer J, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open 2019; 2:e194765. - PMC - PubMed